arrow
M

Martin Schönlein

vienna biocentre
H指数:22
被引数:2,414

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity

化疗诱导衰老通过降低EZH2活性促进急性髓系白血病的免疫原性

2026-09-040
OA
Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2-A Report From the EPICOVIDEHA/EPIRESEHA Registry
2025-12-010
OAAI
Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study

伦伐替尼对比索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌的二线治疗:LEVIATHAN 研究

2025-09-230
OAAI
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (vol 615, pg 168, 2023)

微生物群衍生的3-IAA影响胰腺癌化疗效果(卷 615,页 168,2023)

NATURE
IF48.5
2025-05-130
OA
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity

癌细胞损害单核细胞介导的T细胞刺激以逃避免疫

Nature
IF48.5
2024-11-270
OAAI
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

肝功能失代偿是使用阿特珠单抗联合贝伐单抗治疗的肝细胞癌患者死亡率的主要驱动因素: 成功抗病毒治疗的影响

2024-07-195
PRE
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

肝细胞癌患者与其他晚期实体瘤患者免疫治疗相关肝损伤的特征和结局

2024-03-0111
OA
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI
Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma
2024-02-010
PRE
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

阿特珠单抗/贝伐单抗在先前全身治疗后的HCC患者中的疗效和安全性: 一项全球观察性研究

2023-11-014
OAAI
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
2023-06-1316
OAAI
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

体重指数对接受阿特珠单抗联合贝伐单抗治疗肝细胞癌患者的影响

2023-04-0117
OAAI
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

tixagevimab/cilgavimab对血液系统恶性肿瘤和新型冠状病毒肺炎患者的被动暴露前预防接种: EPICOVIDEHA注册表中的配对分析

2023-04-0113
OAAI
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

新型冠状病毒肺炎血液系统恶性肿瘤患者的尼马曲韦/利托那韦: EPICOVIDEHA登记处的报告

2023-04-0123
OAAI
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry
2023-03-114
OAAI
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
2023-02-2426
OAAI